Talazoparib and Thoracic RT for ES-SCLC

This study is testing whether adding talazoparib (a type of PARP inhibitor drug) to chest radiation therapy improves outcomes for patients with extensive-stage small cell lung cancer (SCLC) who have already completed chemotherapy without disease progression. **You may be eligible if...** - You have been diagnosed with extensive-stage small cell lung cancer - You have completed 4–6 cycles of platinum-based chemotherapy (e.g., carboplatin + etoposide) - Your cancer has not progressed after chemotherapy - You are in reasonably good physical condition (ECOG 0–2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your cancer has spread to the brain (unless previously treated and stable) - You are pregnant or could become pregnant without using contraception - You have had prior chest radiation therapy - You have certain genetic conditions that affect DNA repair Talk to your doctor to see if this trial is right for you.